| Micro-channel |
 |
|
|
|
|
|
| |
| Prescription data tells you: the secret between medicare payments and sales |
| |
| Author：中國銘鉉 企劃部 Release Time：2017-8-30 10:01:47 Number Browse：751 |
| |
On August 30, 2017, the city of Shanghai will include 24 drugs in the health insurance reimbursement directory, which will be used to negotiate drugs for drug prices and target drugs for some tumor molecules.This is the key point of the reimbursement entry for medical expenses in Shanghai, which is the emergence of a standard self-payment standard.
Similar negotiations have been conducted with the previous major diseases in zhejiang, Inner Mongolia, hunan and other provinces. The negotiations in Shanghai have been carried out in accordance with the name of the commodity, and the price of the products has not been publicly listed.The difference is that the way Shanghai announced the result of the negotiation is "commodity name + specification package + individual quota conceited standard".It is the first time that medical insurance payment standards have been introduced.
We can see that some medicines are not low personal standards, especially the original products of multinational companies.How can I better solve this problem?
Another policy of Shanghai health care are also take effect on January 1, 2017 - citizens available medicare voluntary commercial medical insurance personal accounts funds, including major disease insurance and out-of-pocket expenses of be in hospital insurance.For high-priced drugs, the determination of medicare payment standards also clarifies the coverage of commercial health insurance.Allow the citizen to use the individual account of health insurance to purchase commercial insurance, also is through the individual account to improve the benefit of the patient reimbursement treatment.
After the implementation of the health care policy, how the sales of these products will change, whether they can meet the growth expectations, is the focus of corporate managers and investment institutions.
Below we use the hospital prescription analysis system RAS of the China pharmaceutical industry information center to see the changes in sales of several representative drugs after they are included in medicare.
The price of lituximab in 100mg / 10ml is priced at about 3500 yuan in 2017, and the decline reached 55% for patients after entering Shanghai medical insurance.After entering medicare, rituxan performance expectations, in the first quarter of 2017 sales growth of close to 50%, and in 2016, sales of mabthera has two straight quarterly sales growth rate.
Data source: China medical industry information center hospital prescription analysis system RAS
The 440mg (20ml) specification of trastuzumab (herceptin) is priced at around 22,000 yuan in mid-2016, and the personal conceit is 8660, a reduction of 60%.Despite the huge decline, herceptin's 10% growth in the first quarter of 2017 was positive.
Data source: China medical industry information center hospital prescription analysis system RAS
The 100mg * 60 specs of imatinib are priced at about 11000 in mid-2016, and the personal conceit 5060, a decline of 54%, after entering Shanghai health insurance.In the first quarter of 2017, gleevec sales growth reached a staggering 170%, and did not know if it had met novartis's expectations.
Data source: China medical industry information center hospital prescription analysis system RAS
Currently, imatinib has a generic version of the drug, which has been listed in Shanghai health insurance, with a reduction of around 70% in the price of generic drugs such as tianqing, shiyao, and jiangsu hausen.It has grown 200 per cent and its sales are in line.
Data source: China medical industry information center hospital prescription analysis system RAS
Data source: China medical industry information center hospital prescription analysis system RAS
We can see that even if the product declines, even the price is the same, the sales growth of the product is very different.Therefore, if the price of the product is reduced to the medical insurance, it will be possible to obtain the "price change" to realize the sharp increase in product sales and expand market share, which requires the scientific and rigorous investigation and calculation of enterprise science.However, the tracking and analysis of the sales of products after entering medical insurance is of great significance to the price decision of enterprises.
|
| |
Previous article：The household medical device market wins three elements
Next article：Related advisory services for further strengthening of conformity assessment
|
| |
|
|
